H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $11 from $12 and keeps a Buy rating on the shares. The firm adjusted the company’s model post the Q4 report. The Phase 2b RESOLVE study remains on track for a Q3 readout, which is the next key catalyst for the program, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
- Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
- Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
- Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline
- Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness